News

NPX372 received Investigational New Drug Clearance from the FDA, allowing for clinical development.

In an interview, Saad Z. Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated multiple myeloma.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable access barriers.

At 33.6 months' follow-up, patients with standard-risk multiple myeloma had improved progression-free survival outcomes with ciltacabtagene autoleucel vs standard of care.

A retrospective study of tumor-infiltrating lymphocyte therapy showed that despite its benefit, many patients were unable to receive lifileucel.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.

Community oncology delivers high-quality, lower-cost cancer care near home, but faces trial barriers, staff shortages, and rising complexity—driving AI-enabled, partnered transformation.

FDA moves new breast and colorectal cancer therapies forward, while experts spotlight pancreatic precision drugs and belzutifan safety in ccRCC.

Experts debate MMR/p53 testing, liquid biopsy, and immunotherapy sequencing in endometrial cancer, refining prognosis and relapse treatment.

Phase 3 interim data show anbenitamab plus chemo boosts survival and response in previously treated HER2-positive gastric cancer with manageable toxicity.

First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival.

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after a mismatched donor stem cell transplant, showing engraftment, dose-dependent expansion, and persistence.

Study finds income and other financial factors outweigh race in determining cancer trial enrollment, highlighting reforms and simpler trial designs to expand access.

Real-world data show over an 40% response rate for lifileucel TIL therapy, indicating that those treated earlier did better and fewer doses of IL-2 could be used effectively.

FDA strengthens capecitabine and 5‑FU labels: DPD deficiency can trigger fatal toxicity; consider testing, lower doses, and prompt antidote.

During a live event, Andrew H. Lipsky, MD, and participants weigh acalabrutinib, zanubrutinib and pirtobrutinib, comparing real-world side effects, cardiac risks, and dosing tradeoffs.

A phase 2 trial of acalabrutinib led to favorable response rates and tolerability in steroid-refractory chronic GVHD.

CD34+ donor chimerism flags AML relapse early; timely donor lymphocyte infusion boosts MRD-negative remissions and survival after alloHSCT.

A trial of ustekinumab as graft-vs-host disease (GVHD) prophylaxis after hematopoietic cell transplant did not meet its primary end point but showed more favorable outcomes in patients who had myeloablative conditioning.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.

A real-world ciltacabtagene autoleucel (cilta-cel) study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better posttransplant survival despite TP53 mutations.